Advertisement

Acta Neurologica Belgica

, Volume 117, Issue 3, pp 695–702 | Cite as

Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study

  • Meini Zhang
  • Chuntao Zhang
  • Peng Bai
  • Huiru Xue
  • Guilian Wang
Original Article

Abstract

Neuromyelitis optical (NMO) and neuromyelitis optical spectrum disorder (NMOSD) are inflammatory autoimmune demyelination diseases affecting the central nervous system. We investigated the efficiency of low-dose rituximab treatment in 31 Chinese patients with NMO/NMOSD across a median period of 2.29 ± 0.97 years and azathioprine combined with corticosteroid treatment in 34 Chinese patients with NMO/NMOSD across a median period of 2.61 ± 0.94 years. Among the rituximab-treated patients, the mean Expanded Disability Status Scale (EDSS) was 5.62 ± 1.35 before treatment and 4.48 ± 0.78 at last follow-up, and the mean annualized relapse rate (ARR) was 1.39 ± 0.42 before treatment and 0.03 ± 0.13 at last follow-up. Among the azathioprine-treated patients, the mean EDSS was 5.63 ± 1.29 before treatment and 5.05 ± 1.00 at last follow-up, and the mean ARR was 1.28 ± 0.34 before treatment and 0.49 ± 0.21 at last follow-up. In this study, we showed that using low-dosage rituximab could benefit Chinese patients with NMO by reducing the new occurrence of relapses dramatically. Compared with the azathioprine-treated patients, we concluded that rituximab is more effective in preventing NMO relapse and could improve the symptoms.

Keywords

Neuromyelitis optical Low-dosage rituximab Azathioprine Efficiency 

Notes

Acknowledgements

This work was supported by a Grant from the Natural Science Foundation of Shanxi Province, China (Grant Number 2013011052-3).

Author contributions

MZ formulated the study concept, supervised the execution of the study, provided the funding, and wrote the manuscript. CZ and PB recruited the patients, executed the treatment regimen, assessed the patients, and analyzed the patient data during therapy. HX participated in the manuscript preparation. GW processed the blood samples, performed the flow cytometry, and analyzed the laboratory results.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no financial and personal relationships with other people or organizations that can inappropriately influence our work. There is no professional or other personal interest of any nature or kind in any product, service or company that could be construed as influencing the position presented in, or the review of, the manuscript.

Ethical standards

All procedures performed in studies involving human participants were approved by the Shanxi Medical University Ethical Review Board. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Morrow MJ, Wingerchuk D (2012) Neuromyelitis optica. J Neuroophthalmol 32(2):154–166CrossRefPubMedGoogle Scholar
  2. 2.
    Wingerchuk DM, Lennon VA, Lucchinetti CF et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815CrossRefPubMedGoogle Scholar
  3. 3.
    Bizzoco E, Lolli F, Repice AM et al (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256(11):1891–1898CrossRefPubMedGoogle Scholar
  4. 4.
    Lucchinetti CF, Mandler RN, Mcgavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125(Pt 7):1450–1461CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Pittock SJ, Lennon VA, Krecke K et al (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63(3):390–396CrossRefPubMedGoogle Scholar
  6. 6.
    Saadoun S, Bridges LR, Verkman AS et al (2012) Paucity of natural killer and cytotoxic T cells in human neuromyelitis optica lesions. NeuroReport 23(18):1044–1047CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261(1):1–16CrossRefPubMedGoogle Scholar
  8. 8.
    Kimbrough DJ, Fujihara K, Jacob A et al (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1(4):180–187CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Grillo-Lopez AJ (2000) Rituximab: an insider’s historical perspective. Semin Oncol 27(6 Suppl 12):9–16PubMedGoogle Scholar
  10. 10.
    Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131(Pt 11):3072–3080CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76(15):1310–1315CrossRefPubMedGoogle Scholar
  12. 12.
    Cree BA, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7):1270–1272CrossRefPubMedGoogle Scholar
  13. 13.
    Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443–1448CrossRefPubMedGoogle Scholar
  14. 14.
    Kim SH, Kim W, Li XF et al (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68(11):1412–1420CrossRefPubMedGoogle Scholar
  15. 15.
    Bedi GS, Brown AD, Delgado SR et al (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17(10):1225–1230CrossRefPubMedGoogle Scholar
  16. 16.
    Kim SH, Huh SY, Lee SJ et al (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70(9):1110–1117CrossRefPubMedGoogle Scholar
  17. 17.
    Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65(11):1443–1448CrossRefPubMedGoogle Scholar
  18. 18.
    Mealy MA, Wingerchuk DM, Palace J et al (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324–330CrossRefPubMedGoogle Scholar
  19. 19.
    Yang CS, Yang L, Li T et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81(8):710–713CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kim HJ, Kim SH (2014) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 82(6):546–547CrossRefPubMedGoogle Scholar
  21. 21.
    Qiu W, Kermode AG, Li R et al (2015) Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 22(7):1178–1182CrossRefPubMedGoogle Scholar
  22. 22.
    Costanzi C, Matiello M, Lucchinetti CF et al (2011) Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77(7):659–666CrossRefPubMedGoogle Scholar
  23. 23.
    Bichuetti DB, Lobato DOE, Oliveira DM et al (2010) Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 67(9):1131–1136CrossRefPubMedGoogle Scholar
  24. 24.
    Sahraian MA, Moinfar Z, Khorramnia S et al (2010) Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol 17(6):794–799CrossRefPubMedGoogle Scholar
  25. 25.
    Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177–189CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Watanabe S, Misu T, Miyazawa I et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13(8):968–974CrossRefPubMedGoogle Scholar
  27. 27.
    Zephir H, Bernard-Valnet R, Lebrun C et al (2015) Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 262(10):2329–2335CrossRefPubMedGoogle Scholar
  28. 28.
    Mealy MA, Wingerchuk DM, Palace J et al (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324–330CrossRefPubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2017

Authors and Affiliations

  • Meini Zhang
    • 1
  • Chuntao Zhang
    • 1
  • Peng Bai
    • 1
  • Huiru Xue
    • 1
  • Guilian Wang
    • 1
  1. 1.Department of NeurologyFirst Hospital of Shanxi Medical UniversityTaiyuanChina

Personalised recommendations